References
- Dang L, White DW, Gross S, et al. (2009). Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739–44
- Garner RC. (2010). Practical experience of using human microdosing with AMS analysis to obtain early human drug metabolism and PK data. Bioanalysis 2:429–40
- Garner RC, Goris I, Laenen AA, et al. (2002). Evaluation of accelerator mass spectrometry in a human mass balance and pharmacokinetic study-experience with 14C-labeled (R)-6-[amino(4- chlorophenyl)(1-methyl-1H-imidazol-5-yl)methyl]-4-(3-chlorophenyl)-1-methyl-2(1H)-quinolinone (R115777), a farnesyl transferase inhibitor. Drug Metab Dispos 30:823–30
- Geisbrecht BV, Gould SJ. (1999). The human PICD gene encodes a cytoplasmic and peroxisomal NADP(+)-dependent isocitrate dehydrogenase. J Biol Chem 274:30527–33
- Graham RA, Lum BL, Morrison G, et al. (2011). A single dose mass balance study of the Hedgehog pathway inhibitor vismodegib (GDC-0449) in humans using accelerator mass spectrometry. Drug Metab Dispos 39:1460–7
- Gross S, Cairns RA, Minden MD, et al. (2010). Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations. J Exp Med 207:339–44
- Kosmider O, Gelsi-Boyer V, Slama L, et al. (2010). Mutations of IDH1 and IDH2 genes in early and accelerated phases of myelodysplastic syndromes and MDS/myeloproliferative neoplasms. Leukemia 24:1094–6
- Lappin G, Seymour M. (2010). Addressing metabolite safety during first-in-man studies using 14C-labeled drug and accelerator mass spectrometry. Bioanalysis 2:1315–24
- Lappin G, Stevens L. (2008). Biomedical accelerator mass spectrometry: recent applications in metabolism and pharmacokinetics. Expert Opin Drug Metab Toxicol 4:1021–33
- Lin TH, Hu K, Flarakos J, et al. (2013). Assessment of the absorption, metabolism and excretion of [14C]pasireotide in healthy volunteers using accelerator mass spectrometry. Cancer Chemother Pharmacol 72:181–8
- Marcucci G, Maharry K, Wu YZ, et al. (2010). IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 28:2348–55
- Ognibene TJ, Bench G, Vogel JS, et al. (2003). A high-throughput method for the conversion of CO2 obtained from biochemical samples to graphite in septa-sealed vials for quantification of 14C via accelerator mass spectrometry. Anal Chem 75:2192–6
- Pardanani A, Lasho TL, Finke CM, et al. (2010). IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms. Leukemia 24:1146–51
- Parsons DW, Jones S, Zhang X, et al. (2008). An integrated genomic analysis of human glioblastoma multiforme. Science 321:1807–12
- Sharma R, Litchfield J, Bergman A, et al. (2015). Comparison of the circulating metabolite profile of PF-04991532, a hepatoselective glucokinase activator, across preclinical species and humans: potential implications in metabolites in safety testing assessment. Drug Metab Dispos 43:190–8
- Sjöblom T, Jones S, Wood LD, et al. (2006). The consensus coding sequences of human breast and colorectal cancers. Science 314:268–74
- Stein EM. (2016). Molecular pathways: IDH2 mutations-co-opting cellular metabolism for malignant transformation. Clin Cancer Res 22:16–19
- Tse S, Leung L, Raje S, et al. (2014). Disposition and metabolic profiling of [14C]cerlapirdine using accelerator mass spectrometry. Drug Metab Dispos 42:2023–32
- Wang F, Travins J, Delabarre B, et al. (2013). Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 340:622–6
- Ward PS, Patel J, Wise DR, et al. (2010). The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225–34
- Welch JS, Ley TJ, Link DC, et al. (2012). The origin and evolution of mutations in acute myeloid leukemia. Cell 150:264–78
- Yan H, Parsons DW, Jin G, et al. (2009). IDH1 and IDH2 mutations in gliomas. N Engl J Med 360:765–73
- Yoshihara T, Hamamoto T, Munakata R, et al. (2001). Localization of cytosolic NADP-dependent isocitrate dehydrogenase in the peroxisomes of rat liver cells: biochemical and immunocytochemical studies. J Histochem Cytochem 49:1123–31